Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: A case report

Giuseppe Nucera, Vincenzo Dario Mandato, Maria Carolina Gelli, Stefano Palomba, Giovanni Battista La Sala

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.

Original languageEnglish
Pages (from-to)219-221
Number of pages3
JournalGynecological Endocrinology
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Levonorgestrel
Intrauterine Devices
Fertilization in Vitro
Endometrial Neoplasms
Gonadotropin-Releasing Hormone
Endometrioid Carcinoma
Ovulation Induction
Ovariectomy
Hysterectomy
Fertility
Pregnancy

Keywords

  • Endometrial cancer
  • Fertility
  • GnRH-a
  • IVF
  • LNG-IUD

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynaecology

Cite this

@article{91c3a1d18da940c1835df7dd206d4409,
title = "Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: A case report",
abstract = "Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.",
keywords = "Endometrial cancer, Fertility, GnRH-a, IVF, LNG-IUD",
author = "Giuseppe Nucera and Mandato, {Vincenzo Dario} and Gelli, {Maria Carolina} and Stefano Palomba and {La Sala}, {Giovanni Battista}",
year = "2013",
month = "3",
doi = "10.3109/09513590.2012.738726",
language = "English",
volume = "29",
pages = "219--221",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient

T2 - A case report

AU - Nucera, Giuseppe

AU - Mandato, Vincenzo Dario

AU - Gelli, Maria Carolina

AU - Palomba, Stefano

AU - La Sala, Giovanni Battista

PY - 2013/3

Y1 - 2013/3

N2 - Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.

AB - Background: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. Case: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up. Conclusion: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.

KW - Endometrial cancer

KW - Fertility

KW - GnRH-a

KW - IVF

KW - LNG-IUD

UR - http://www.scopus.com/inward/record.url?scp=84874293475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874293475&partnerID=8YFLogxK

U2 - 10.3109/09513590.2012.738726

DO - 10.3109/09513590.2012.738726

M3 - Article

C2 - 23153053

AN - SCOPUS:84874293475

VL - 29

SP - 219

EP - 221

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 3

ER -